{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:28:08Z","timestamp":1784546888695,"version":"3.55.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Heart failure (HF) is the final stage of various cardiac diseases with poor prognosis. The integrated traditional Chinese medicine (TCM) and western medicine therapy has been considered as a prospective therapeutic strategy for chronic heart failure (CHF). There have been small clinical trials and experimental studies to demonstrate the efficacy of Shenfu Qiangxin Pills (SFQX) for treating CHF, however, there is still a lack of further high-quality trial. This paper describes the protocol for the clinical assessment of SFQX in CHF (heart-kidney Yang deficiency syndrome) patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A randomized, double-blind, parallel-group, placebo-controlled, multi-center trial will assess the efficacy and safety of SFQX in the treatment of CHF. 352 patients with CHF (heart-kidney Yang deficiency syndrome) from 22 hospitals in China will be enrolled. Besides their standardized western medicine, patients will be randomized to receive treatment of either SFQX or placebo for 12 weeks. The primary outcome is the plasma N-terminal pro-B-type natriuretic peptide levels, which will be measured uniformly by the central laboratory. The secondary outcomes include composite endpoint events (hospitalization due to worsening HF, all-cause mortality, other serious cardiovascular events), echocardiography indicators, grades of the New York Heart Association (NYHA) functional classification, the 6-minute walk test (6MWT) results, Minnesota Living With Heart Failure Questionnaire and TCM syndrome scores.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>The integrated TCM and western medicine therapy has developed into a treatment model in China. The rigorous design of the trial will assure an objective and scientific assessment of the efficacy and safety of SFQX in the treatment of CHF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>Chinese Clinical Trial Registry: ChiCTR2000028777 (registered on January 3, 2020).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020271","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T03:20:57Z","timestamp":1590636057000},"page":"e20271","source":"Crossref","is-referenced-by-count":19,"title":["A multi-center, randomized, double-blind, placebo-parallel controlled trial for the efficacy and safety of shenfuqiangxin pills in the treatment of chronic heart failure (Heart-Kidney yang deficiency syndrome)"],"prefix":"10.1097","volume":"99","author":[{"given":"Lijun","family":"Guo","sequence":"first","affiliation":[{"name":"National Priority R & D Programmes (2018YFC1707410-02), Cardiovascular Disease Center, Xiyuan Hospital of China Academy of Chinese Medical Sciences"},{"name":"National Priority R & D Programmes (2018YFC1707410-02), Xiyuan Clinical Medical College of Beijing University of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yuan","sequence":"additional","affiliation":[{"name":"National Priority R & D Programmes (2018YFC1707410-02), Cardiovascular Disease Center, Xiyuan Hospital of China Academy of Chinese Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawu","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Priority R & D Programmes (2018YFC1707410-02), Cardiovascular Disease Center, Xiyuan Hospital of China Academy of Chinese Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"National priority R & D programmes (2018YFC1707410-02), Fuwai Hospital of Chinese Academy of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Hua","sequence":"additional","affiliation":[{"name":"National Priority R & D Programmes (2018YFC1707410-02), Xuanwu Hospital Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochang","family":"Ma","sequence":"additional","affiliation":[{"name":"National Priority R & D Programmes (2018YFC1707410-02), Cardiovascular Disease Center, Xiyuan Hospital of China Academy of Chinese Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keji","family":"Chen","sequence":"additional","affiliation":[{"name":"National Priority R & D Programmes (2018YFC1707410-02), Cardiovascular Disease Center, Xiyuan Hospital of China Academy of Chinese Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"R1-20240521","first-page":"760","article-title":"Chinese guidelines for the diagnosis and management of heart failure 2018","volume":"46","year":"2018","journal-title":"Chin J Cardiol"},{"key":"R2-20240521","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.cardfail.2017.09.014","article-title":"Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China heart failure (China-HF) Registry","volume":"23","author":"Zhang","year":"2017","journal-title":"J Card Fail"},{"key":"R3-20240521","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2015","journal-title":"Esc Heart Failure"},{"key":"R4-20240521","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"R5-20240521","first-page":"133","article-title":"Expert consensus on diagnosis and treatment of integrated traditional and western medicine in chronic heart failure","volume":"36","year":"2016","journal-title":"Chin J Integr Tradit West Med"},{"key":"R6-20240521","first-page":"1616","article-title":"Effects of Shenfu Qiangxin pill on Bcl-2\/Bax apoptosis in rats with cardiac and renal syndrome","volume":"22","author":"Wang","year":"2016","journal-title":"J Bas Chin Med"},{"key":"R7-20240521","first-page":"121","article-title":"Shenfu Qiangxin pill inhibits heart and kidney cells apoptosis by regulating rennin receptor-mediated MAPK signal pathway","volume":"22","author":"Wang","year":"2016","journal-title":"Chin J Exp Tradit Med Formulae"},{"key":"R8-20240521","first-page":"2602","article-title":"Effects of Shenfu Qiangxin pills on the expression of LC3b and Bax in myocardial cells of rats with cardio-renal syndrome","volume":"27","author":"Li","year":"2016","journal-title":"China Pharm"},{"key":"R9-20240521","first-page":"230","article-title":"Effects of Shenfu Qiangxin pills on cardiac function in patients with chronic heart failure","volume":"8","author":"Wang","year":"2001","journal-title":"Chin J Integr Tradit West Med Inten Crit Care"},{"key":"R10-20240521","first-page":"158","article-title":"Clinical study of Shenfu Qiangxin pills","volume":"22","author":"Song","year":"1991","journal-title":"Chin Tradit Her Drugs"},{"key":"R11-20240521","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1016\/j.jacc.2017.04.041","article-title":"Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms","volume":"69","author":"Hao","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R12-20240521","first-page":"1258","article-title":"Expert consensus on diagnosis and treatment of traditional Chinese medicine in chronic heart failure","volume":"55","year":"2014","journal-title":"J Tradit Chin Med"},{"key":"R13-20240521","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jacc.2013.05.035","article-title":"A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of Qili Qiangxin capsules in patients with chronic heart failure","volume":"62","author":"Li","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R14-20240521","first-page":"5115","article-title":"A review of Chinese herbal medicine for the treatment of chronic heart failure","volume":"23","author":"Wang","year":"2017","journal-title":"Curr Pharm Des"},{"key":"R15-20240521","first-page":"765","article-title":"Efficacy assessment of Shenfu Qiangxin pills combined with benazepril hydrochloride in the treatment of hypertension with heart failure in the elderly","volume":"7","author":"Wu","year":"2018","journal-title":"Chin J Clin Lab Sci (Electronic Edition)"},{"key":"R16-20240521","first-page":"3250","article-title":"Clinical study of Shenfu Qiangxin pills combined with carvedilol in the treatment of congestive heart failure","volume":"34","author":"Wang","year":"2019","journal-title":"Drugs Clin"},{"key":"R17-20240521","first-page":"988","article-title":"Clinical study of Shenfu Qiangxin pills combined with levosimendan in the treatment of refractory heart failure","volume":"34","author":"Liu","year":"2019","journal-title":"Drugs Clin"},{"key":"R18-20240521","first-page":"204","article-title":"Regulating effect of Shenfu Qiangxin pills on neural endocrine and related factors of chronic heart failure","volume":"20","author":"Deng","year":"2014","journal-title":"Chin J Exp Tradit Med Formulae"},{"key":"R19-20240521","first-page":"891","article-title":"Effects of Shenfu Qiangxin pill on angiotensin II and brain natriuretic of chronic heart failure patients","volume":"32","author":"Chen","year":"2014","journal-title":"Chin Arch Tradit Chin Med"},{"key":"R20-20240521","first-page":"10","article-title":"Clinical effects of Shenfu Qiangxin pills combined with western medicine on oxidative stress injury, vascular endothelial function and inflammatory cytokines in patients with chronic heart failure","volume":"9","author":"Chen","year":"2017","journal-title":"Clin J Chin Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T20:02:50Z","timestamp":1716321770000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":20,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020271","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]}}}